Use of cyclosporine in uterine transplantation.
| Autor: | Saso S; Division of Surgery, Oncology, Reproductive Biology and Anaesthetics, Department of Surgery and Cancer, Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK., Logan K, Abdallah Y, Louis LS, Ghaem-Maghami S, Smith JR, Del Priore G |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of transplantation [J Transplant] 2012; Vol. 2012, pp. 134936. Date of Electronic Publication: 2011 Nov 10. |
| DOI: | 10.1155/2012/134936 |
| Abstrakt: | Uterine transplantation has been proposed as a possible solution to absolute uterine factor infertility untreatable by any other option. Since the first human attempt in 2000, various teams have tried to clarify which immunosuppressant would be most suitable for protecting the allogeneic uterine graft while posing a minimal risk to the fetus. Cyclosporine A (CsA) is an immunosuppressant widely used by transplant recipients. It is currently being tested as a potential immunosuppressant to be used during UTn. Its effect on the mother and fetus and its influence upon the graft during pregnancy have been of major concern. We review the role of CsA in UTn and its effect on pregnant transplant recipients and their offspring. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|